Mechanical heart valve thrombosis and novel oral anticoagulants: A word of caution

Interventional Cardiology (London)

Volumn 5, Issue 1, 2013, Pages 9-12

  Toeg, Hadi Daood ^a   Boodhwani, Munir ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

guidelines; mechanical valve; oral anticoagulation; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; HEPARIN; PHENINDIONE; RIVAROXABAN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; AUTOPSY; BLOOD CLOTTING; BRAIN EMBOLISM; CASE REPORT; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DYSPNEA; ECHOCARDIOGRAPHY; FOREIGN BODY; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; MALE; MITRAL VALVE REPLACEMENT; OFF LABEL DRUG USE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTHETIC VALVE DYSFUNCTION; PROSTHETIC VALVE THROMBOSIS; REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; UNSTABLE ANGINA PECTORIS; VALVED CONDUIT; WEAKNESS;

EID: 84874057721     PISSN: 17555302     EISSN: 17555310     Source Type: Journal    
DOI: 10.2217/ica.12.81     Document Type: Review

References (14)

1. Skanes AC, Healey JS, Cairns JA et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 28(2), 125-136 (2012).
2. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009).
3. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981-992 (2011).
4. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364(9), 806-817 (2011).
5. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883-891 (2011).
6. Furie KL, Goldstein LB, Albers GW et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43(12), 3442-3453 (2012).
7. McKellar SH, Abel S, Camp CL et al. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J. Thorac. Cardiovasc. Surg. 141(6), 1410-1416 (2011).
8. Schomburg JL, Medina EM, Lahti MT, Bianco RW. Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model. J. Invest. Surg. 25(3), 150-155 (2012).
9. Maegdefessel L, Linde T, Krapiec F et al. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb. Res. 126(3), e196-e200 (2010).
10. Kaeberich A, Reindl I, Raaz U et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J. Thromb. Thrombolysis. 32(4), 417-425 (2011).
11. Price J, Hynes M, Labinaz M, Ruel M, Boodhwani M. Mechanical valve thrombosis with dabigatran. J. Am. Coll. Cardiol. 60(17), 1710-1711 (2012).
12. Chu JW Chen VH, Bunton R. Thrombosis of a mechanical heart valve despite dabigatran. Ann. Intern. Med. 157(4), 304 (2012).
13. Stewart RA, Astell H, Young L, White HD. Thrombosis on a mechanical aortic valve whilst anti-coagulated with dabigatran. Heart Lung Circ. 21(1), 53-55 (2012).
14. Van de Werf F, Brueckmann M, Connolly SJ et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, Phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am. Heart J. 163(6), 931-937.e1 (2012).